|
|
 |
|
Viewing report
|
|
|
|
Healthcare Reform in the US - Impact on Pricing and Reimbursement
GlobalData, April 2011, Pages: 5
Healthcare Reform in the US - Impact on Pricing and Reimbursement
Summary
On 23 March, 2010, the Obama administration brought into effect the Patient Protection and Affordable Care Act (PPACA), followed shortly by the Reconciliation Act of 2010 (H.R. 4872) on 30 March, both designed to overhaul the system of healthcare to address problems with access to medical help and drug reimbursement. It is likely to be the most significant piece of legislation passed by the Obama administration, and has far reaching consequences for patients, healthcare professionals and industry alike. In total, the Congressional Budget Office (CBO) expects the bill to cost approximately $938 billion, which should mean a reduction in the federal deficit of around $138 billion over the next decade. However, this calculation is a point of contention between different groups.
Scope
- The pharmaceutical industry has naturally been concerned about the introduction of healthcare reform and the possible impact it may have on their revenues. As a result, various large pharmaceutical companies have been negotiating with the government, recognizing that in order to remain successful under the new system they must make sacrifices in some areas in terms of pricing. To this end, concessions in areas such as closing the reimbursement gap in the Medicare Part D plan have been made. There are positives and negatives for the industry under the reforms.
Reasons to buy
- Gives impact analysis of Pricing and Reimbursement due to Healthcare Reform in the US
|
|
|
|
